In addition to its lead compound series, IB1000, IntraBio has developed a robust pipeline of compounds.
IB2000s: The IB2000 (Diferuloylmethane analogues) series has demonstrated clinical efficacy and safety in observational studies for Ménière’s disease.
IB3000s: The IB3000 series (NAADP analogues and agonists) have demonstrated in pre-clinical studies enormous potential to elucidate new molecular pathways, thereby creating opportunities to treat a wide range of diseases from Type 2 Diabetes to autism, to neurodegenerative disorders.
IB4000: IB4000 (UDCA) has been used in observational clinical studies for the treatment of NPC liver dysfunction, showing clinical efficacy and safety. IB4000 has been granted Orphan Drug Designation in both the US and EU for the treatment of NPC.
IB5000: IB500 (Betahistine combination therapy) has demonstrated clinical efficacy and safety in observational studies for Ménière’s disease.